BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 36468211)

  • 21. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
    Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    Angeli D; Salvi S; Tedaldi G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
    Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
    JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.
    Hansford S; Kaurah P; Li-Chang H; Woo M; Senz J; Pinheiro H; Schrader KA; Schaeffer DF; Shumansky K; Zogopoulos G; Santos TA; Claro I; Carvalho J; Nielsen C; Padilla S; Lum A; Talhouk A; Baker-Lange K; Richardson S; Lewis I; Lindor NM; Pennell E; MacMillan A; Fernandez B; Keller G; Lynch H; Shah SP; Guilford P; Gallinger S; Corso G; Roviello F; Caldas C; Oliveira C; Pharoah PD; Huntsman DG
    JAMA Oncol; 2015 Apr; 1(1):23-32. PubMed ID: 26182300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.
    Kurian AW; Abrahamse P; Ward KC; Hamilton AS; Deapen D; Berek JS; Hoang L; Yussuf A; Dolinsky J; Brown K; Slavin T; Hofer TP; Katz SJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34977446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women.
    Fu F; Zhang D; Hu L; Sundaram S; Ying D; Zhang Y; Fu S; Zhang J; Yao L; Xu Y; Xie Y
    Cancer Biol Med; 2021 Oct; 19(2):253-62. PubMed ID: 34606182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
    Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic testing by cancer site: stomach.
    Chun N; Ford JM
    Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.
    Wang X; Teer JK; Tousignant RN; Levin AM; Boulware D; Chitale DA; Shaw BM; Chen Z; Zhang Y; Blakeley JO; Acosta MT; Messiaen LM; Korf BR; Tainsky MA
    Genes Chromosomes Cancer; 2018 Jan; 57(1):19-27. PubMed ID: 28891274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.
    Irelli A; Patruno LV; Chiatamone Ranieri S; Di Giacomo D; Malatesta S; Alesse E; Tessitore A; Cannita K
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    Wood ME; McKinnon W; Garber J
    Breast J; 2020 Aug; 26(8):1528-1534. PubMed ID: 32741080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational advances regarding hereditary breast cancer syndromes.
    Gage M; Wattendorf D; Henry LR
    J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    Pietragalla A; Arcieri M; Marchetti C; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Nov; 30(11):1803-1810. PubMed ID: 32895312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
    Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
    J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.